(C) Lundbeck 2013 - Barbara Jaszewski

Network intelligence for Lundbeck’s new drugs
Time is tight for Andreas Eggert and Barbara Jaszewski

January 2013. The success of its new drugs against alcohol abuse critically depends on the Danish drugmaker's capability to outbeat generics and more distinctive improvements than other branded therapeutics after market launch. Time is tight for Andreas Eggert and Barbara Jaszewski, his new colleague for global Pricing and Market Access.



If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 1 page

Full Company License enquire here

Back to section

Related Editorial Articles

Merck: Getting closer to biosimilars markets in Asia and Latin America

AstraZeneca and MedImmune Trigger Public Investments into Brazil's Translational Healthcare

Novo Nordisk: Doing our business a little bit differently than the others in industry
Mads Krogsgård Thomsen on business models different to companies like Eli Lilly, Pfizer, or Eli Lilly, Sanofi-Aventis. The case of stem cell therapeutics.

Bayer AG: New Stakes in Stem Cells
Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Horizon Discovery: Mitigating risks and developing the U.S. business

Roche Ethiopia: Build-up of an emerging market

Philip Wood to Push Haemophilia Business of Swedish Orphan Biovitrum and Biogen Idec